New drug BGB-B455 targets tough tumors in early trial
NCT ID NCT06803680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose, then checking how well the drug works against the tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-B455
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have the CLDN6 protein.
What could go wrong
This is a very early Phase 1 trial with only 90 participants, so it is not yet known if BGB-B455 is safe or effective. Many early-stage drugs do not move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Adventhealth
RECRUITINGCelebration, Florida, 34747-4606, United States
-
Avera Cancer Institute
RECRUITINGSioux Falls, South Dakota, 57105-2108, United States
-
Beijing Cancer Hospital
COMPLETEDBeijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109-4433, United States
-
Fudan University Shanghai Cancer Centerpudong
RECRUITINGShanghai, Shanghai Municipality, 201321, China
-
Liverpool Hospital
RECRUITINGLiverpool, New South Wales, NSW 2170, Australia
-
Mater Cancer Care Centre
RECRUITINGSouth Brisbane, Queensland, QLD 4101, Australia
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229-6028, United States
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030013, China
-
Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107-4307, United States
-
Sun Yat Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
RECRUITINGNanchang, Jiangxi, 330006, China